Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for maternal reactivity to infant signals in postpartum depression
NL-OMON53882Phase 2Completed
- Sponsor
- Radboud University
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in postpartum depression (PPD) (2 arms), sponsored by Radboud University. Primary endpoints: Maternal sensitivity during interaction with own infant, Maternal sensitivity during interaction with crying infant simulator and 3 more. Started May 2023; status: completed.
02
Drugs
oxytocin
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NL-OMON53882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53882.